# DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

> **NCT05764057** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 450 (estimated)

## Conditions studied

- AMI
- STEMI
- NSTEMI
- Left Ventricular Dysfunction

## Interventions

- **DRUG:** Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT05764057
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2026-10-12
- **Final completion:** 2026-10-12
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764057, "DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05764057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*